The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints

Classical Hodgkin lymphoma is curable in the majority of cases with chemotherapy and/or radiation. However, 15-20% of patients ultimately relapse and succumb to their disease. Pathologically, classical Hodgkin lymphoma is characterized by rare tumor-initiating Reed-Sternberg cells surrounded by a de...

Full description

Saved in:
Bibliographic Details
Published in:Haematologica (Roma) 2016-07, Vol.101 (7), p.794-802
Main Authors: Vardhana, Santosha, Younes, Anas
Format: Article
Language:English
Subjects:
Animals
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
B-Lymphocytes - drug effects
B-Lymphocytes - immunology
B-Lymphocytes - metabolism
Biomarkers
Combined Modality Therapy
Hodgkin Disease - drug therapy
Hodgkin Disease - immunology
Hodgkin Disease - metabolism
Hodgkin Disease - pathology
Humans
Immunomodulation - drug effects
Immunotherapy
Molecular Targeted Therapy
Review
T-Lymphocytes - drug effects
T-Lymphocytes - immunology
T-Lymphocytes - metabolism
Tumor Microenvironment - drug effects
Tumor Microenvironment - immunology
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Classical Hodgkin lymphoma is curable in the majority of cases with chemotherapy and/or radiation. However, 15-20% of patients ultimately relapse and succumb to their disease. Pathologically, classical Hodgkin lymphoma is characterized by rare tumor-initiating Reed-Sternberg cells surrounded by a dense immune microenvironment. However, the role of the immune microenvironment, particularly T and B cells, in either promoting or restricting Classical Hodgkin lymphoma growth remains undefined. Recent dramatic clinical responses seen using monoclonal antibodies against PD-1, a cell surface receptor whose primary function is to restrict T cell activation, have reignited questions regarding the function of the adaptive immune system in classical Hodgkin lymphoma. This review summarizes what is known regarding T cells, B cells, and immune checkpoints in classical Hodgkin lymphoma.
ISSN:0390-6078
1592-8721
DOI:10.3324/haematol.2015.132761